Pulnovo Medical Welcomes New Investor EQT Following CE-MDR Approval to Expand Pulmonary Hypertension Solutions

Pulnovo Medical Welcomes EQT as a New Investor

Pulnovo Medical, a renowned name in medical devices for pulmonary hypertension (PH) and heart failure (HF), recently celebrated a significant milestone with the approval of CE-MDR (Medical Device Regulation) in Europe. This achievement coincides with their announcement of a new investment partnership with EQT Group, a leading global private equity firm, while concurrently maintaining support from Qiming Venture Partners.

This partnership marks a pivotal step for Pulnovo Medical as it strives to expand treatment options for patients suffering from pulmonary hypertension—a condition that remains critically underserved globally. The investment from EQT will provide substantial support for international clinical studies, regulatory approvals, and the commercialization of Pulnovo’s innovative medical solutions.

Background of Pulnovo Medical
Founded in 2013, Pulnovo Medical has dedicated its research efforts to addressing significant unmet clinical needs within cardiovascular care. Central to its innovation is the development of advanced medical devices based on the Pulmonary Artery Denervation (PADN) technology. Achievements to date include recognition from the US FDA as a Breakthrough Device in 2021 and designation as a Humanitarian Use Device in 2023. Their catheter and generator received approval in late 2023 from China's National Medical Products Administration (NMPA), followed by the FDA's approval of a 9F sheath in 2024. The recent CE-MDR certification obtained in March 2025 is a key milestone that lays the groundwork for global commercialization.

EQT's Role in the Partnership
Zoe Zhu, a director in the EQT Private Capital Asia advisory team, highlighted the critical clinical need for improved solutions for patients dealing with pulmonary hypertension and heart failure. The PADN solution developed by Pulnovo offers new hope through its demonstrated clinical efficacy and growing acceptance within the global medical community. EQT is keen to leverage its extensive healthcare and life sciences expertise, and global network to advance Pulnovo’s mission to provide novel cardiovascular solutions to patients worldwide.

Future Aspirations
Cynthia Chen, the CEO of Pulnovo Medical, expressed immense gratitude toward EQT and Qiming Venture Partners for their unwavering support and partnership. "From the very beginning, Pulnovo Medical has focused on addressing real, unmet clinical needs by developing original, scalable, and evidence-based solutions grounded in frontline care. While translating clinically driven innovations into global standards is challenging, we remain committed to providing meaningful, scientifically validated medical value to patients around the world," Chen stated.

As Pulnovo Medical embarks on this new chapter, the combination of EQT's investment and continued support from Qiming Venture Partners will undoubtedly accelerate their global expansion efforts and enhance treatment options for patients facing the challenges of pulmonary hypertension. The collaboration promises to drive innovations that can transform cardiovascular care and bring new hope to numerous patients in need.

In conclusion, this partnership is not just a financial transaction; it is a commitment to pioneering research and development in medical technology that resonates deeply with the core mission of Pulnovo Medical. By confronting the enduring challenges in cardiovascular healthcare, they aspire to lead the way in making significant, positive differences in the lives of patients worldwide.